These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11425271)

  • 21. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer.
    Huiping C; Sigurgeirsdottir JR; Jonasson JG; Eiriksdottir G; Johannsdottir JT; Egilsson V; Ingvarsson S
    Br J Cancer; 1999 Dec; 81(7):1103-10. PubMed ID: 10584868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.
    Gatalica Z; Lele SM; Rampy BA; Norris BA
    Cancer; 2000 Mar; 88(6):1378-83. PubMed ID: 10717620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma.
    Yang Q; Yoshimura G; Suzuma T; Tamaki T; Umemura T; Nakamura M; Nakamura Y; Wang X; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2001 Dec; 7(12):3869-73. PubMed ID: 11751477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma.
    Scholes AG; Liloglou T; Maloney P; Hagan S; Nunn J; Hiscott P; Damato BE; Grierson I; Field JK
    Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2472-7. PubMed ID: 11581185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma.
    Yatsuoka T; Sunamura M; Furukawa T; Fukushige S; Yokoyama T; Inoue H; Shibuya K; Takeda K; Matsuno S; Horii A
    Am J Gastroenterol; 2000 Aug; 95(8):2080-5. PubMed ID: 10950061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: analysis of loss of heterozygosity.
    Smeds J; Wärnberg F; Norberg T; Nordgren H; Holmberg L; Bergh J
    Acta Oncol; 2005; 44(1):41-9. PubMed ID: 15848905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.
    Isaacs C; Cavalli LR; Cohen Y; Pennanen M; Shankar LK; Freedman M; Singh B; Liu M; Gallagher A; Rone JD; Dickson RB; Sidransky D; Haddad BR
    Breast Cancer Res Treat; 2004 Mar; 84(2):99-105. PubMed ID: 14999140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis.
    Winqvist R; Hampton GM; Mannermaa A; Blanco G; Alavaikko M; Kiviniemi H; Taskinen PJ; Evans GA; Wright FA; Newsham I
    Cancer Res; 1995 Jun; 55(12):2660-4. PubMed ID: 7780982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
    Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
    Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease.
    Campiglio M; Pekarsky Y; Menard S; Tagliabue E; Pilotti S; Croce CM
    Cancer Res; 1999 Aug; 59(16):3866-9. PubMed ID: 10463571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
    Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
    Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of FHIT allelic imbalance/loss of heterozygosity and FHIT expression in cutaneous squamous cell carcinomas.
    Gray SE; Kay E; Leader M; Mabruk M
    J Cutan Pathol; 2008 Sep; 35(9):816-25. PubMed ID: 18494825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced FHIT expression is associated with tumor progression in sporadic colon adenocarcinoma.
    Kapitanović S; Čačev T; Lončar B; Catela Ivković T; Križanac Š; Pavelić K
    Exp Mol Pathol; 2014 Feb; 96(1):92-7. PubMed ID: 24370550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concordant loss of fragile gene expression early in breast cancer development.
    Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
    Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FHIT alterations in breast cancer.
    Ingvarsson S
    Semin Cancer Biol; 2001 Oct; 11(5):361-6. PubMed ID: 11562178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients.
    Hampl JA; Hampl M; Reiss G; Koch R; Saeger HD; Schackert HK
    Anticancer Res; 2004; 24(1):281-90. PubMed ID: 15015609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of heterozygosity on chromosome 17p13 in breast carcinomas identifies tumors with high proliferation index.
    Merlo GR; Venesio T; Bernardi A; Canale L; Gaglia P; Lauro D; Cappa AP; Callahan R; Liscia DS
    Am J Pathol; 1992 Jan; 140(1):215-23. PubMed ID: 1731526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.
    Cavalli LR; Singh B; Isaacs C; Dickson RB; Haddad BR
    Cancer Genet Cytogenet; 2004 Feb; 149(1):38-43. PubMed ID: 15104281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy.
    Oudin C; Bonnetain F; Boidot R; Végran F; Soubeyrand MS; Arnould L; Riedinger JM; Lizard-Nacol S
    Int J Oncol; 2007 May; 30(5):1145-51. PubMed ID: 17390016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.